Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

★ 3 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Ann Oncol

Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS

doi: 10.1016/j.annonc.2024.08.2243

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A

doi: 10.1016/j.lungcan.2025.108548

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Lung Cancer

Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, Gori S, Giannarelli D, Novello S, Passiglia F

doi: 10.1016/j.lungcan.2025.108576

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Eur J Cancer

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC

doi: 10.1016/j.ejca.2025.115266

Lung, Respiratory and Thoracic Cancer

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

J Clin Oncol

Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H, Thoracic Oncology Research Group and all ACHILLES investigators

doi: 10.1200/JCO-24-02007

Lung, Respiratory and Thoracic Cancer

Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101

Oncologist

Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S

doi: 10.1093/oncolo/oyaf029

Lung, Respiratory and Thoracic Cancer

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Lung Cancer

Vaes RDW, Cortiula F, Lyu S, Hiltermann TJN, Houben R, Degens J, Hendriks LEL, Ruysscher D

doi: 10.1016/j.lungcan.2025.108541

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Front Oncol

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

doi: 10.3389/fonc.2025.1526931

Lung, Respiratory and Thoracic Cancer

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Lung Cancer

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D

doi: 10.1016/j.lungcan.2024.107950

Related content

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834

Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective